SCHEMBL286959

SCHEMBL286959

Cc1nc(Cl)ccc1C#N

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
ALDH1A1 P00352 1/20 0.41
RPS6KA5 O75582 1/20 0.38
RPS6KA4 O75676 1/20 0.38
TSHR P16473 1/20 0.37
IDH1 O75874 6/20 0.36
TRPV4 Q9HBA0 1/20 0.36
AR P10275 2/20 0.36
CYP11B2 P19099 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CSNK1A1 P48729 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2708620 0.80 RPS6KA5 (0.39) NPSR1CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL3509665 0.78 CHRNB2 (0.33) TSHR
SCHEMBL559359 0.78 NOS3 (0.52) NPSR1CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL1403877 0.78 TSHR (0.37) NPSR1CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL1641172 0.77 HRH4 (0.45) NPSR1CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL30376853 0.77 ALDH1A1 (0.43) NPSR1CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL565602 0.77 ALDH1A1 (0.43) NPSR1CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL31253097 0.77 HRH4 (0.45) NPSR1CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL21928096 0.76 EGLN2 (0.40) NPSR1CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL21657144 0.74 TSHR (0.37) NPSR1CYP1A2CYP2C9CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055094-A1 FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2026-02-26 US disclosed
EP-4444708-B1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER (US) 2025-07-30 EP disclosed
US-12358903-B2 FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2025-07-15 US disclosed
US-20250129048-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2025-04-24 US disclosed
EP-4444708-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF Pfizer Inc. (US) 2024-10-16 EP disclosed
CN-118369317-A Melanocortin 4 receptor antagonists and uses thereof 辉瑞大药厂 2024-07-19 CN disclosed
WO-2023229380-A1 HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF 주식회사 엘지화학 2023-11-30 WO disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
WO-2023105387-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2023-06-15 WO disclosed
WO-2023105387-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2023-06-15 WO disclosed
EP-1218360-B1 TRIAZINE KINASE INHIBITORS AMGEN INC (US) 2008-05-28 EP disclosed
WO-2008053300-A1 PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2008-05-08 WO disclosed
US-20070129409-A1 Androgen receptor modulators HU LAIN-YEN 2007-06-07 US disclosed
CN-1942442-A Insecticidal N-substituted sulfenimides DOW AGROSCIENCES LLC (US) 2007-04-04 CN disclosed
EP-0446604-A2 Pyridine and related aza heterocycle derivatives as cardiovascular agents AMERICAN CYANAMID COMPANY (US) 1991-09-18 EP disclosed
US-4716170-A 5-[1H-(5-membered-N-aromatic heteryl)-1-yl]-1,6-naphthyridin-2(1H)-ones and their cardiotonic use STERLING DRUG INC. (US) 1987-12-29 US disclosed
US-4697021-A 1,6-dihydro-6-oxo-3-pyridinecarbonitriles, intermediates for cardiotonic agents STERLING DRUG INC. (US) 1987-09-29 US disclosed
US-4657915-A INOTROPIC AGENTS STERLING DRUG INC. (US) 1987-04-14 US disclosed
US-4634772-A 2-[2-(di-lower-alkylamino)-1-propenyl]-6-methoxy-3-pyridinecarbonitriles, intermediates for cardiotonic agents STERLING DRUG INC. (US) 1987-01-06 US disclosed
EP-0189853-A2 1,6-Naphthyridin-2(1H)-ones having cardiotonic activity and preparation STERLING DRUG INC. (US) 1986-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129409-A1 Androgen receptor modulators AR, FSHR, NR5A1 NPSR1 229/4885CYP1A2 450/4885CYP2C9 1983/4885
US-12358903-B2 FXR (NR1H4) modulating compounds NR1H4, NR1H2, NR1H3 NPSR1 736/4885CYP1A2 1763/4885CYP2C9 3352/4885
US-20260055094-A1 FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H2, NR1H3 NPSR1 477/4885CYP1A2 1339/4885CYP2C9 2240/4885
US-20250129048-A1 MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF MC4R, MC3R, MC2R NPSR1 60/4885CYP1A2 1995/4885CYP2C9 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.